New estimates of the costs of adverse events in patients with cancer

The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	PloS one Ročník 20; číslo 9; s. e0332703
Hlavní autori:	Patel, Achal, Schuldt, Robert, Sussell, Jesse
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Public Library of Science 29.09.2025 Public Library of Science (PLoS)
Predmet:	Adult Adverse and side effects Adverse events Aged Allergic reactions Allergies Availability Cancer Cancer therapies Care and treatment Chronic lymphocytic leukemia Cost assessments Costs Critical components Data acquisition Drug-Related Side Effects and Adverse Reactions - economics Drugs Economic models Economics Estimates Female Forecasts and trends Health Care Costs Health care expenditures Health care policy Health problems Health services Hodgkin's lymphoma Humans Leukemia Lymphatic leukemia Lymphoma Male Medical diagnosis Medical economics Medicare Melanoma Middle Aged Multiple myeloma Nausea Neoplasms - drug therapy Neoplasms - economics Oncology Patients Photosensitivity Regulatory approval Tumors United States United States Italy
ISSN:	1932-6203, 1932-6203
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with ≥ 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with ≥ 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models.
AbstractList	The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with ≥ 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with ≥ 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models. The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with [greater than or equal to] 100 treatment episodes) ranged from -$488 for photosensitivity to $ 29,331 for allergic reaction. Incremental costs for severe AEs (with [greater than or equal to] 50 treatment episodes) ranged from$16 for dizziness to $ 18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models. The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with ≥ 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with ≥ 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models.The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these costs exist. Previous studies focused on costs related to specific AEs, cancer types, or treatment regimens. This study assesses the incremental costs of AEs across 13 cancer types by applying the most current diagnosis schema (International Statistical Classification of Diseases and Related Health Problems [ICD-10]) to patients diagnosed between 2016 and 2022. Data were acquired from US insurance claims and included adult patients who were diagnosed and treated for breast, pancreatic, bladder, lung, prostate, colorectal, skin, liver, head and neck, non-Hodgkin lymphoma, follicular lymphoma, multiple myeloma, or chronic lymphocytic leukemia cancer. We selected 54 AEs for analysis based on their frequency of occurrence, relevance based on severity, and availability of ICD-10 diagnostic codes. We matched patient treatment episodes (the period from initiation of a distinct treatment regimen until discontinuation, change of treatment, or end of data availability) for patients experiencing a specific AE to treatment episodes of similar patients not experiencing that same AE in a 1:1 ratio. We generated estimates for AEs of any severity, severe AEs, and individual tumor types. Our analyses evaluate 392,566 treatment episodes from 110,791 patients. In pooled analyses across tumor types, incremental costs for AEs of any severity (with ≥ 100 treatment episodes) ranged from - $488 for photosensitivity to $29,331 for allergic reaction. Incremental costs for severe AEs (with ≥ 50 treatment episodes) ranged from $16 for dizziness to $18,841 for gastrointestinal bleeding. This study provides a comprehensive assessment of the economic burden of AEs in cancer care and generates a range of estimates to be used as inputs in future economic models.
Audience	Academic
Author	Sussell, Jesse Schuldt, Robert Patel, Achal
Author_xml	– sequence: 1 givenname: Achal orcidid: 0009-0006-4803-3540 surname: Patel fullname: Patel, Achal – sequence: 2 givenname: Robert orcidid: 0000-0002-4416-4897 surname: Schuldt fullname: Schuldt, Robert – sequence: 3 givenname: Jesse surname: Sussell fullname: Sussell, Jesse
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/41021622$$D View this record in MEDLINE/PubMed
BookMark	eNqNkttqGzEQhkVJaRK3b1DahUJpL-zqsNJqL0N6MoQGeroVWu3IllmvXEmbw9tXtjchLrkoutDo59OM5tecoqPe94DQS4JnhFXkw8oPodfdbJPlGWaMVpg9QSekZnQqKGZHD-JjdBrjCmPOpBDP0HFJMCWC0hP08RtcFxCTW-sEsfC2SEsojI9pd9DtFYQIBVxBnxXXFxud3C6-dmlZGN0bCM_RU6u7CC_GfYJ-ff708_zr9OLyy_z87GJquJRpKrSRQleEcihrbomVVV0TibE1tm41SE4BOG-tNW0FmrQS0xoy0DQSg27ZBL3e5910PqrRgKgY5byiFGcTJmi-J1qvV2oTclvhVnnt1E7wYaF0SM50oBompNUNbjilpamaGmphSIuxoLwCQ3Kud2O14P8M2SO1dtFA1-ke_DCWrWWVXZ2gN_-gjz9upBY613e99Slos02qziSvBKlLUmZq9giVVwtrZ_JnW5f1gwvvDy5kJsFNWughRjX_8f3_2cvfh-zbB-wSdJeW0XdDcr6Ph-CrsfuhWUN7b_vdlGWg3AMm-BgD2HuEYLUd5ju71HaY1TjM7C_QluNZ
Cites_doi	10.1093/oncolo/oyac186 10.1097/MD.0000000000011736 10.1016/j.lungcan.2018.02.011 10.1002/onco.13812 10.1080/13696998.2016.1192548 10.1186/s13561-024-00481-y 10.1186/2193-1801-3-259 10.1016/j.jval.2017.12.009 10.1016/j.ygyno.2007.08.056 10.1542/peds.2004-2514 10.1371/journal.pone.0196007 10.1080/13696998.2016.1225577 10.2217/fon-2019-0434 10.1016/j.cllc.2018.05.016 10.3390/pharma2020012 10.1371/journal.pone.0199598
ContentType	Journal Article
Copyright	Copyright: © 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2025 Public Library of Science 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: Copyright: © 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2025 Public Library of Science – notice: 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 DOA
DOI	10.1371/journal.pone.0332703
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) SciTech Premium Collection ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Health Research Premium Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agriculture Science Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Databases ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE MEDLINE - Academic Agricultural Science Database
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General) Economics
EISSN	1932-6203
ExternalDocumentID	3255722003 oai_doaj_org_article_b368fab0b5224c7b9e96c1d006257ec1 A857619414 41021622 10_1371_journal_pone_0332703
Genre	Journal Article
GeographicLocations	United States Italy
GeographicLocations_xml	– name: United States – name: Italy
GroupedDBID	--- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ CGR CUY CVF ECM EIF ESTFP IPNFZ NPM RIG 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO ADCSY AGGLG
ID	FETCH-LOGICAL-c588t-6ac86a7125e495f1f87991800fcf9dae852ee55dffcd7ea1d8029e180bb80ead3
IEDL.DBID	FPL
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001584455200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1932-6203
IngestDate	Wed Dec 10 15:00:31 EST 2025 Tue Oct 07 09:24:59 EDT 2025 Tue Sep 30 19:05:25 EDT 2025 Tue Oct 07 09:06:56 EDT 2025 Sat Nov 29 13:44:01 EST 2025 Sat Nov 29 10:28:43 EST 2025 Wed Nov 26 10:44:16 EST 2025 Wed Nov 26 10:44:49 EST 2025 Tue Oct 14 02:10:55 EDT 2025 Sat Oct 04 02:10:22 EDT 2025 Sat Nov 29 07:26:00 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Language	English
License	Copyright: © 2025 Patel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c588t-6ac86a7125e495f1f87991800fcf9dae852ee55dffcd7ea1d8029e180bb80ead3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-4416-4897 0009-0006-4803-3540
OpenAccessLink	http://dx.doi.org/10.1371/journal.pone.0332703
PMID	41021622
PQID	3255722003
PQPubID	1436336
PageCount	e0332703
ParticipantIDs	plos_journals_3255722003 doaj_primary_oai_doaj_org_article_b368fab0b5224c7b9e96c1d006257ec1 proquest_miscellaneous_3255798705 proquest_journals_3255722003 gale_infotracmisc_A857619414 gale_infotracacademiconefile_A857619414 gale_incontextgauss_ISR_A857619414 gale_incontextgauss_IOV_A857619414 gale_healthsolutions_A857619414 pubmed_primary_41021622 crossref_primary_10_1371_journal_pone_0332703
PublicationCentury	2000
PublicationDate	2025-09-29
PublicationDateYYYYMMDD	2025-09-29
PublicationDate_xml	– month: 09 year: 2025 text: 2025-09-29 day: 29
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: San Francisco
PublicationTitle	PloS one
PublicationTitleAlternate	PLoS One
PublicationYear	2025
Publisher	Public Library of Science Public Library of Science (PLoS)
Publisher_xml	– name: Public Library of Science – name: Public Library of Science (PLoS)
References	EL Jewell (pone.0332703.ref009) 2007; 107 M Durand (pone.0332703.ref007) 2024; 14 P Richard (pone.0332703.ref010) 2018; 13 SF Abu (pone.0332703.ref006) 2023; 2 H Borghaei (pone.0332703.ref011) 2018; 119 DE Irwin (pone.0332703.ref013) 2016; 19 LS Lal (pone.0332703.ref014) 2022; 5 P Grivas (pone.0332703.ref015) 2019; 15 B Arondekar (pone.0332703.ref002) 2015; 21 S George (pone.0332703.ref018) 2021; 26 D Latremouille-Viau (pone.0332703.ref017) 2017; 20 A Arunachalam (pone.0332703.ref020) 2018; 19 NM Engel-Nitz (pone.0332703.ref019) 2020; 26 YM Yim (pone.0332703.ref012) 2016; 27 Jr Garrison LP (pone.0332703.ref001) 2018; 21 C Copley-Merriman (pone.0332703.ref003) 2018; 97 RN Hansen (pone.0332703.ref016) 2014; 3 W Wong (pone.0332703.ref005) 2018; 13 B McGregor (pone.0332703.ref004) 2023; 28 CW Shepard (pone.0332703.ref008) 2005; 115
References_xml	– volume: 28 start-page: 72 issue: 1 year: 2023 ident: pone.0332703.ref004 article-title: Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma publication-title: Oncologist doi: 10.1093/oncolo/oyac186 – volume: 26 start-page: 729 issue: 6 year: 2020 ident: pone.0332703.ref019 article-title: Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer publication-title: J Manag Care Spec Pharm – volume: 97 issue: 31 year: 2018 ident: pone.0332703.ref003 article-title: Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000011736 – volume: 119 start-page: 112 year: 2018 ident: pone.0332703.ref011 article-title: Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2018.02.011 – volume: 5 issue: 5 year: 2022 ident: pone.0332703.ref014 article-title: Healthcare costs related to adverse events in hepatocellular carcinoma treatment: a retrospective observational claims study publication-title: Cancer Reports – volume: 26 issue: 7 year: 2021 ident: pone.0332703.ref018 article-title: The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors publication-title: Oncologist doi: 10.1002/onco.13812 – volume: 19 start-page: 1027 issue: 11 year: 2016 ident: pone.0332703.ref013 article-title: Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries publication-title: J Med Econ doi: 10.1080/13696998.2016.1192548 – volume: 14 start-page: 11 issue: 1 year: 2024 ident: pone.0332703.ref007 article-title: Evaluating the costs of adverse drug events in hospitalized patients: a systematic review publication-title: Health Econ Rev doi: 10.1186/s13561-024-00481-y – volume: 3 start-page: 259 year: 2014 ident: pone.0332703.ref016 article-title: Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens publication-title: Springerplus doi: 10.1186/2193-1801-3-259 – volume: 21 start-page: 161 issue: 2 year: 2018 ident: pone.0332703.ref001 article-title: A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7] publication-title: Value Health doi: 10.1016/j.jval.2017.12.009 – volume: 107 start-page: 532 issue: 3 year: 2007 ident: pone.0332703.ref009 article-title: Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2007.08.056 – volume: 115 start-page: 1220 issue: 5 year: 2005 ident: pone.0332703.ref008 article-title: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States publication-title: Pediatrics doi: 10.1542/peds.2004-2514 – volume: 21 start-page: 158 issue: 2 year: 2015 ident: pone.0332703.ref002 article-title: Economic burden associated with adverse events in patients with metastatic melanoma publication-title: J Manag Care Spec Pharm – volume: 13 issue: 4 year: 2018 ident: pone.0332703.ref005 article-title: Assessment of costs associated with adverse events in patients with cancer publication-title: PLoS One doi: 10.1371/journal.pone.0196007 – volume: 27 year: 2016 ident: pone.0332703.ref012 article-title: Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC) publication-title: Ann Oncol – volume: 20 start-page: 54 issue: 1 year: 2017 ident: pone.0332703.ref017 article-title: The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States publication-title: J Med Econ doi: 10.1080/13696998.2016.1225577 – volume: 15 start-page: 3809 issue: 33 year: 2019 ident: pone.0332703.ref015 article-title: Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA publication-title: Future Oncol doi: 10.2217/fon-2019-0434 – volume: 19 issue: 5 year: 2018 ident: pone.0332703.ref020 article-title: Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2018.05.016 – volume: 2 start-page: 120 issue: 2 year: 2023 ident: pone.0332703.ref006 article-title: Cost estimations of managing adverse drug reactions in hospitalized patients: a systematic review of study methods and their influences publication-title: Pharmacoepidemiology doi: 10.3390/pharma2020012 – volume: 13 issue: 6 year: 2018 ident: pone.0332703.ref010 article-title: The burden of out of pocket costs and medical debt faced by households with chronic health conditions in the United States publication-title: PLoS One doi: 10.1371/journal.pone.0199598
SSID	ssj0053866
Score	2.4887207
Snippet	The cost of adverse events (AEs) is a critical component of healthcare economic models for cancer treatment; however, few comprehensive estimates of these...
SourceID	plos doaj proquest gale pubmed crossref
SourceType	Open Website Aggregation Database Index Database
StartPage	e0332703
SubjectTerms	Adult Adverse and side effects Adverse events Aged Allergic reactions Allergies Availability Cancer Cancer therapies Care and treatment Chronic lymphocytic leukemia Cost assessments Costs Critical components Data acquisition Drug-Related Side Effects and Adverse Reactions - economics Drugs Economic models Economics Estimates Female Forecasts and trends Health Care Costs Health care expenditures Health care policy Health problems Health services Hodgkin's lymphoma Humans Leukemia Lymphatic leukemia Lymphoma Male Medical diagnosis Medical economics Medicare Melanoma Middle Aged Multiple myeloma Nausea Neoplasms - drug therapy Neoplasms - economics Oncology Patients Photosensitivity Regulatory approval Tumors United States
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQigMXRHk1tIBBSMAhbR6OH8fyqEBCBfFSb5bj2KgSJKt1lt_fGceJWAkEB44bz0a738zY3yT2N4Q8cR1w_IKxXAlV5LAEyFxyW-SmMJJJ5Vtmo7r-O3F2Js_P1YdfWn3hnrBJHngC7ritufSmLVogCsyKVjnFbdnh2b9GOBsLn0KouZia5mDIYs7TQblalMfJL0froXdHRV1XYm6SlRaiqNe_zMqr9fch_JlyxqXn9Aa5njgjPZl-6x654vqbZC9lZaDPknT081vkFcxZFHUzfiCFpIOnwO-oHcIYPxjsvhwcjapNgV70NMmqBorPY6nFENjcJl9OX39--SZPfRJy20g55txYyY0AquKg3PGllwJYHzBBb73qjJNN5VzTdN7bTjhTdrKolAODtpUFRFJ9h6x6QGafUGeKqpXMurIxrLbM2Lrjqq1bX9UcmGBG8hk0vZ7kMHR8JyagjJjQ0AiyTiBn5AUiu9iimHW8AC7WycX6by7OyEP0i55Ohi4pqU9kEx_ClCwjj6MFClr0uGPmm9mGoN--__oPRp8-7hg9TUZ-GDfGmnRKAf4TCmXtWB7uWEJa2p3hfYyiGZWgayjeRIV7AeGbc2T9fvjRMow3xV1wvRu2yUbBDNtk5O4UkQuyDHu086q69z8QPyDXKuxzjG_f1CFZjZutu0-u2p_jRdg8iKl2CWcuKtg priority: 102 providerName: Directory of Open Access Journals – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgQYIL0PJooIBBSNBD2iROYvuEyqMCCZWKl3qLbMeuKkGyxFl-PzOOs2glQEgcN55EG8_DX-yZbwh5YlvA-FlZppLLLIUlQKSiNlmqMiVKIZ0uTWDXf8ePj8XpqTyJG24-plXOMTEE6rY3uEd-wAD78gJTqZ4vv6fYNQpPV2MLjYvkErIkFCF172SOxODLdR3L5RjPD6J29pd9Z_czxgo-t8qKy1Fg7V_H5sXya-__DDzDAnR0_X__-g1yLUJPejjZyha5YLttcmWuTPbbZCs6uqfPIhv13k3yCsIgRSqOb4hKae8oQEZqej-GHwobOntLAxGUp-cdjUytnuIWLzVoVcMt8vno9aeXb9LYeiE1lRBjWisjasUB_Vj4gnK5ExyAJIBLZ5xslRVVYW1Vtc6ZlluVtyIrpAUBrUUGxsluk0UH07xDqFVZoUVpbF6pkplSGdbWUjPtClYDuExIOmugWU4MG004ZuPwZTLNTIMaa6LGEvIC1bSWRX7scKEfzprobo1mtXBKZxrgZWm4llbWJm-xYrTi1uQJeYhKbqZi07WXN4eiCvs6eZmQx0ECOTI6TMI5Uyvvm7fvv_yD0McPG0JPo5Drx0EZFQsf4J2Qe2tDcndDEjzdbAzvoEnOs-KbX4YFd86m9_vhR-thfCgm1nW2X0UZCUG7SsidybzXM1ti2_e6KO7-_eH3yNUCmyLjUZ3cJYtxWNn75LL5MZ774UHwyJ9WuDx3 priority: 102 providerName: ProQuest
Title	New estimates of the costs of adverse events in patients with cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/41021622 https://www.proquest.com/docview/3255722003 https://www.proquest.com/docview/3255798705 https://doaj.org/article/b368fab0b5224c7b9e96c1d006257ec1 http://dx.doi.org/10.1371/journal.pone.0332703
Volume	20
WOSCitedRecordID	wos001584455200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest advanced technologies & aerospace journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LbxMxELYgRYIL0AJtoASDkIDDpvv049iURlRtwyqFKnBZeb1eVAl2ozjh9zPjOEFBRILLSInH2ex4xv78mM-EvDYVYPwwTQPJZRjAECACwXQYqFCJVMi6TLVj17_go5GYTGT-e6L4xw5-wqMjb9P-tG1MP0ySmCO5506cMIZXNQzzi1XPC7HLmE-P21ZzY_hxLP3rvrgz_d7a7UDTDTjDB__7Vx-S-x5a0uOlL-ySW6bZI3dXmcd2j-z6QLb0rWebfveIvIdujiLVxg9EnbStKUBCqls7dx8UXthsDXVET5beNNQzsVqKS7hUo9fMHpPPw9NPJx8Cf7VCoDMh5gFTWjDFAd0YmCHVUS04AEUAj7WuZaWMyGJjsqyqa11xo6JKhLE0oFCWIgTnS56QTgNveUCoUWFcilSbKFNpolOlk4rJMilraCIAj10SrCxeTJcMGoXbRuMw81hapkCDFd5gXTLAZlnrIv-1-wIsXfhwKsqEiVqVYQnwMdW8lEYyHVWYEZpxo6MueYGNWiyTSddRXByLzK3bRGmXvHIayIHR4CGbb2phbXH28foflK7GG0pvvFLdzmdKK5_YAO-E3FobmocbmhDJeqP4AF1wZRVbJDDf4zEeH4SaK7f8e_HLdTH-KB6ca0y78DoSOuWsS_aX7ry2bIrXurM4frr9uc_IvRgvPMZtOHlIOvPZwjwnd_TP-Y2d9chtPr5GOeFOCpDiJOqRncHpKB_33AJHz8UoyPNBH-RleI6S505egcyzr1AjP7vMv_wCGJ43XQ
linkProvider	Public Library of Science
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VBalcgBZoFwo1CAQc0ubhJPYBoUKputrtgqCg3lLHcapKkCzrXRB_it_ITOIsWgkQlx44Jp5Yynjmm7E9D4BHpkAf3-fck6n0PTQBwhOJ9j3lK8GFLHOum-r6o3Q8Ficn8u0K_OhyYSisssPEBqiLWtMZ-W6Evm8aUijVi8kXj7pG0e1q10KjFYuh-f4Nt2z2-WAf1_dxGB68Pn516LmuAp6OhZh5idIiUSkadoObgzIoRYo-EvpNpS5loYyIQ2PiuChLXaRGBYXwQ2mQIM-Fj3yPcN5LcJnjxotCyI78YYf8iB1J4tLzojTYddKwM6krs-NHUZh2rbmc-Wu6BCxsQW_yqbZ_dnQbg3dw_X9j1Q245lxrttfqwhqsmGodVrvMa7sOaw7ILHvqqm0_uwn7CPOMSo18Jq-b1SVDl5jp2s6aB0UNq61hTaEry84r5irRWkZH2EyT1kxvwYcL-bPb0KtwWTeBGeWHueDaBLHikeZKR0Ui8ygvwyhB57kPXrfi2aStIJI114gp7rxazmQkIZmTkD68JLFY0FL97-ZFPT3LHJxkeZSIUuV-ju4z12kujUx0UFBGbJwaHfRhm4Qqa5NpFyiW7Ym4ObcKeB8eNhRUA6SiIKMzNbc2G7z5-A9E798tET1xRGU9myqtXGIH_hPVFlui3FqiRCTTS8ObpAIdV2z2S5Dxy07Ufz_8YDFMk1LgYGXquaORaJTiPmy06rTgLKe29kkY3vn75Nuwenh8NMpGg_HwLlwNqQE0XUvKLejNpnNzD67or7NzO73foAGD04vWqZ_1SZuc
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGQcALsHFZYTCDQMBD1sS52HlAaFAqqk2lYoD2FhzHniZBUuoWxF_j13GO4xRVAsTLHnhMfGIpx-fy2T4XQh7qCjB-mCRBzvMwABcgApGpMJChFInITZkoV13_kE8m4vg4n26QH10uDIZVdjbRGeqqUXhGPogB-3KGoVQD48MipsPR89mXADtI4U1r106jFZED_f0bbN_ss_EQ1voRY6NX716-DnyHgUClQiyCTCqRSQ5OXsNGwURGcMBLgKGMMnkltUiZ1mlaGaMqrmVUiZDlGgjKUoSwBjHMe46c50kWMhc2OO28ANiRLPOpejGPBl4y9mZNrffCOGa8a9PlXaHrGLDyC73Zp8b-GfQ65ze6-j-z7Rq54iE33W91ZJNs6HqLXOoysu0W2fQGztInvgr30-tkCOafYgmSz4jGaWMoQGWqGrtwDxIbWVtNXQEsS09r6ivUWopH21ShNs1vkPdn8mc3Sa-GJd4mVMuQlSJROkplEqtEqrjK8jIuDYszANV9EnSrX8zayiKFu17ksCNrOVOgtBReWvrkBYrIihbrgrsXzfyk8GamKONMGFmGJcDqRPEy13mmogozZVOuVdQnuyhgRZtku7Juxb5I3XlWlPTJA0eBtUFqFJcTubS2GL_58A9ER2_XiB57ItMs5lJJn_AB_4Q1x9Yod9YowcKpteFtVIeOK7b4JdTwZSf2vx--vxrGSTGgsNbN0tPk4KzSPrnVqtaKswm2u88Yu_33yXfJRVCl4nA8ObhDLjPsC423lfkO6S3mS32XXFBfF6d2fs8ZBko-nrVK_QS1N6Rz
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+estimates+of+the+costs+of+adverse+events+in+patients+with+cancer&rft.jtitle=PloS+one&rft.au=Patel%2C+Achal&rft.au=Schuldt%2C+Robert&rft.au=Sussell%2C+Jesse&rft.date=2025-09-29&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=20&rft.issue=9&rft.spage=e0332703&rft_id=info:doi/10.1371%2Fjournal.pone.0332703&rft.externalDocID=A857619414
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon